公开(公告)号：US20240301079A1

公开(公告)日：2024-09-12

申请号：US18540730

申请日：2023-12-14

申请人： Roche GlycArt AG

发明人： Pablo UMAÑA ,  Peter BRÚNKER ,  Claudia FERRARA KOLLER ,  Tobias SUTER ,  Ursula PÚNTENER ,  Ekkehard MÓSSNER

IPC分类号： C07K16/28 ,  A61K39/00 ,  C12N9/10 ,  C12N15/11 ,  C12N15/63

CPC分类号： C07K16/2887 ,  C12N9/1051 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/01 ,  C12N15/11 ,  C12N15/63 ,  C12Y204/01144 ,  Y10S530/808 ,  Y10S530/866 ,  Y10S530/867

摘要： The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.